//
sign in
Post
by @danabra.mov
PostEmbed
by @danabra.mov
Record
by @jimpick.com
Record
by @atsui.org
+ new component
Post
EPCORE DLBCL-1: #EHA2026: Epcoritamab outperformed investigator’s choice of CIT in relapsed/refractory large B-cell lymphoma, improving PFS and delivering durable complete responses. ✅ Higher CR rate ✅ More durable remissions ✅ 27% PFS at 3 years Read more: www.onclive.com/view/epcorit...
2d
Epcoritamab improved PFS and produced durable complete responses vs chemoimmunotherapy in relapsed/refractory large B-cell lymphoma.
Epcoritamab Significantly Improves PFS Vs Chemoimmunotherapy in R/R Large B-Cell Lymphoma | OncLive
www.onclive.com
OncLive